Physician profile
Lenar T Yessayan
NPI 1023210861
$40,351.99
in general payments reported to CMS, 2019-2025
7 companies · $25K in 2025
The $25K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.14 · 2021: $249 · 2022: $2,704 · 2023: $1,953 · 2024: $11K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $21K · Consulting Fee: $6,800 · Travel and Lodging: $4,175 · Food and Beverage: $2,870 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $20,637.50 |
| Consulting Fee | $6,800.00 |
| Travel and Lodging | $4,175.41 |
| Food and Beverage | $2,870.09 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,850.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vantive US Healthcare LLC | $24,380.32 | 2025 | Renal - Acute |
| Baxter Healthcare | $9,088.22 | 2019-2024 | Renal - Acute |
| Fresenius USA Marketing, INC. | $5,833.83 | 2021-2024 | |
| Exthera Medical Corporation | $297.82 | 2023 | |
| Mallinckrodt Hospital Products INC. | $264.51 | 2024-2025 | Terlivaz |
| Nxstage Medical, INC. | $245.31 | 2025 | Nxstage System One |
| Amgen INC. | $241.98 | 2023-2025 | Aranesp, Parsabiv, Tavneos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lenar Yessayan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.